GV129606 is a new parenteral trinem antibiotic belonging to the ␤-lactam class. It combines broad-spectrum activity (against gram-negative and -positive bacteria, aerobes and anaerobes), with high potency and resistance to ␤-lactamases. Comparative in vitro and in vivo antibacterial activities were determined for GV129606 against more than 400 recent clinical isolates (aerobes, including ␤-lactamase producers, and anaerobes), using representative antibacterial agents (meropenem, piperacillin, ceftazidime, cefpirome, ciprofloxacin, and gentamicin for aerobes and metronidazole, cefoxitin, piperacillin, and clindamycin for anaerobes). Against methicillin-susceptible staphylococci and streptococci, GV129606 and meropenem were the most active of the drugs tested. GV129606 showed an MIC for 90% of strains tested (MIC 90 ) ranging from <0.015 to 0.06 g/ml against methicillin-susceptible staphylococci and Streptococcus sanguis, Streptococcus pyogenes, and Streptococcus agalactiae. Against penicillin-susceptible and -resistant Streptococcus pneumoniae isolates, GV129606, meropenem, and cefpirome showed MIC 90 s of <0.015 and 1 g/ml, respectively. Meropenem was the most active compound against members of the family Enterobacteriaceae with MIC 90 s of <0.5 g/ml. Against these species, GV129606 possessed activity superior to those of piperacillin, ceftazidime, cefpirome, and gentamicin, with MIC 90 s of <8 g/ml, but its activity was two-to sixfold less than that of ciprofloxacin (with the exception of Proteus rettgeri and Providencia stuartii). Haemophilus spp., Moraxella catarrhalis, Neisseria gonorrhoeae, and Pseudomonas aeruginosa were also included in the spectrum of GV129606. GV129606 showed good antianaerobe activity, similar to metronidazole. It was stable against all clinically relevant ␤-lactamases (similar to meropenem). The in vitro activity was confirmed in vivo against septicemia infections induced in mice by selected gram-positive and -negative bacteria with 50% effective doses (ED 50 s) of <0.05 and <0.5 mg/kg of body weight/dose, respectively. GV129606 was as effective as meropenem against septicemia in mice caused by ceftazidime-resistant Pseudomonas aeruginosa, exhibiting an ED 50 of 0.33 mg/kg/dose.
In the current climate of increasing antibiotic resistance in bacterial pathogens, there is growing need for novel, effective antimicrobials (11, 13, 14) . Consequently, considerable attention has been focused on extended-spectrum ␤-lactams, such as the carbapenems, as clinically useful drugs which might be manipulated to generate novel antibacterial agents with an enhanced clinical chemotherapeutic utility.
Following this strategy, our search for a novel antibacterial has led to the discovery of a new class of ␤-lactam derivatives containing a tricyclic nucleus as the key structural feature, namely, trinems. The first trinem to proceed to full development was sanfetrinem (GV104326) (4S,8S,9R,10S,12R)-4-(methoxy)-10-(1-hydroxyethyl)-11-oxo-1-azatricyclo [7. 2.0.0 3, 8 ] undec-2-ene-2-carboxylic acid which was selected as the most promising member of this class (9) . It is a highly potent agent exhibiting a broad spectrum of activity against a wide range of gram-positive and -negative bacteria (excluding Pseudomonas), aerobes and anaerobes (2) . The antibacterial profile of sanfetrinem includes a notable potency against the most commonly implicated bacteria of community-acquired respiratory tract infections, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis (3, 12) , and when formulated as the hexetil ester (sanfetrinem cilexetil), it is particularly suited for oral therapy of these infections. Sanfetrinem cilexetil is currently undergoing development principally for use in community-acquired respiratory tract infections.
After discovery of sanfetrinem, the research program turned its attention to exploit the full potential of the series to identify a potentially parenteral antibiotic. This required a strategy which would increase the potency and broaden the spectra of the early analogs to include Pseudomonas species. A number of formamidino analogs were therefore prepared. GV129606 was selected as the best example and has been extensively evaluated in vitro and in vivo. It differs from sanfetrinem by having a 4-[(iminomethyl)methylamino] group (Fig. 1 ). It exhibits a particularly broad spectrum, high potency, insensitivity to the clinically most important ␤-lactamases, and good efficacy against septicemia caused by relevant clinical pathogens in mice.
MATERIALS AND METHODS
Organisms. The aerobic bacterial strains used for susceptibility testing were clinical isolates from Italian hospitals taken during the period from 1992 to 1994. The most relevant pathogens and strains resistant to ␤-lactams (methicillinresistant staphylococci and organisms resistant to broad-spectrum cephalosporins), which represent the current clinical picture, were also included. Their identification was confirmed by using API strips 20E, 20NE, STAPH, and STREP (API Ltd., Basingstoke, England). The isolates were maintained as lyophilized cultures and before use were subcultured twice on blood agar base (BBL, Cockeysville, Md.), except for fastidious species which were grown on blood agar base supplemented with 5% defibrinated sheep blood (Oxoid, Ltd., Basingstoke, England), and Haemophilus spp., which were grown on chocolate agar (Oxoid). Recent anaerobic clinical isolates from Italian hospitals were identified by using AN-ident and ID32A (API) and stored at Ϫ80°C until required.
Antibiotics. GV129606 was synthesized at GlaxoWellcome SpA (Verona, Italy). Meropenem, piperacillin, ceftazidime, cefpirome, ciprofloxacin, gentamicin, cefoxitin, and metronidazole were obtained commercially from Zeneca, Irbi, GlaxoWellcome, Hoechst, Bayer, Schering Plough, Merck Sharp Dohme, and Pharmacia, respectively. Antibiotic solutions were prepared in sterile 0.1 M potassium phosphate buffer, pH 7.4, or according to the manufacturer's recommendation, on the day of use.
In vitro susceptibility tests. MICs were determined by the agar dilution technique with Mueller-Hinton agar (MHA) (BBL), according to the technical procedures recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (6) . Serial doubling dilutions, in sterile 0.1 M potassium phosphate buffer, pH 7.4, were prepared from antibiotic solutions to obtain concentrations ranging from 32 to 0.015 g/ml. Most determinations were made with MHA (BBL), but for certain strains, this was supplemented as specified by the NCCLS with 5% defibrinated blood sheep for S. pneumoniae and Haemophilus test medium (HTM) (Oxoid) for Haemophilus spp.
The inoculum was prepared by diluting cultures grown overnight to obtain a concentration of 10 7 to 10 8 CFU/ml corresponding to 0.5 McFarland standards. The inocula were transferred with a multipoint inoculator (Denley, Billingshurst, Sussex, United Kingdom) delivering 10 4 to 10 5 CFU/spot onto agar plates containing serial doubling antibiotic dilutions ranging from 32 to 0.015 g/ml or lower; the plates were incubated at 35°C in air (except for streptococci, enterococci, and haemophili, which were incubated in 5% CO 2 ).
For the anaerobic bacteria, MICs were determined by an agar dilution technique with Wilkins-Chalgren (WC) agar (Difco Laboratories, Detroit, Mich.) by the method recommended by the NCCLS (7). The bacterial inocula were prepared by directly suspending colonies grown on WC agar into WC broth to give a 0.5 McFarland standard (1.5 ϫ 10 8 bacteria per ml). Inocula were transferred with a multipoint inoculator onto WC agar plates containing serial doubling antibiotic dilutions (ranging from 32 to 0.015 g/ml). The plates were then incubated at 35°C in an atmosphere of 80% N 2 , 10% CO 2 , and 10% H 2 . The MIC was defined as the lowest drug concentration which inhibited visible growth of microorganisms, disregarding a single colony or a faint haze caused by inoculum.
In vivo activity. The in vivo activities of the antibiotics were determined against organisms causing bacteremic infection in mice. Male CD1 albino mice (Charles River) weighing 18 to 22 g, (five mice in each group) were injected intraperitoneally with 28 to 150 times the 50% lethal dose of the bacteria, which were suspended in 8% hog gastric mucin (Difco) (4% for S. pneumoniae and Pseudomonas aeruginosa). The test antibiotics were administered subcutaneously in 0.25 ml after 1 and 5 h (for P. aeruginosa after 1, 3, and 5 h) postchallenge. All untreated mice died within 2 days after infection. The survival of the infected mice was monitored for 4 days, and the 50% effective dose (ED 50 ) was determined from the final survival rates by the Probit method (4) .
The research complied with national legislation and with the company policy on the Care and Use of Animals and with related codes of practice. 
RESULTS
In vitro antibacterial activity. The susceptibilities of 115 recent gram-positive clinical isolates to GV129606 and other comparative agents are shown in Table 1 . A feature of GV129606 is its in vitro activity against gram-positive cocci. Methicillinsusceptible Staphylococcus aureus strains (including penicillinase producers), Staphylococcus epidermidis, and Staphylococcus haemolyticus, were highly susceptible to GV129606 (cumulative MIC for 90% of strains tested [MIC 90 ] of Յ0.015 g/ml). Against these species, GV129606 was more active than any of the other injectable antibiotics tested. Methicillin-resistant S. aureus isolates were only weakly susceptible to all ␤-lactams tested, including GV129606, with MIC 90 s ranging from 8 to Ͼ32 g/ml. Of the antibiotics tested, only ciprofloxacin and gentamicin showed significant activity in vitro against methicillin-resistant S. aureus. Streptococci were highly susceptible to GV129606, meropenem, and cefpirome. The MIC 90 s of GV129606 were Յ0.015 g/ml against penicillin-susceptible Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus agalactiae and 0.06 g/ml against Streptococcus sanguis. In comparison, meropenem and cefpirome showed an MIC 90 similar to those of GV129606 against S. pneumoniae and S. pyogenes but showed MIC 90 s two-or fourfold higher against other Streptococcus spp. Ciprofloxacin and gentamicin were the least active of the compounds tested against pneumococci. The MIC 90 of GV129606 against penicillin-resistant S. pneumoniae was similar to those of meropenem and cefpirome (MIC 90 , 1 g/ml), with piperacillin, ceftazidime, gentamicin, and ciprofloxacin being up to eightfold less active. Enterococcus faecalis was moderately susceptible to GV129606, meropenem, piperacillin, and ciprofloxacin (MIC 90 s, 8, 8, 4 , and 2 g/ml, respectively).
The susceptibilities of the major pathogenic gram-negative species to GV129606 compared with meropenem, piperacillin, ceftazidime, cefpirome, gentamicin, and ciprofloxacin are reported in Table 2 .
Members of the family Enterobacteriaceae were highly susceptible to GV129606. The MIC 90 s for Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, and Citrobacter diversus were in the range 0.06 to 0.5 g/ml. The Proteeae were slightly less susceptible; the MIC 90 ranges for Proteus mirabilis, Proteus vulgaris, Morganella morganii, Proteus rettgeri, and Providencia stuartii were 1 to 8 g/ml. Meropenem was the most active compound tested against the Enterobacteriaceae exhibiting two-to fourfold more activity than GV129606 against E. coli, K. pneumoniae, K. oxytoca, E. cloacae, E. aero- morganii were two-to fourfold more susceptible to ciprofloxacin than GV129606, whereas GV129606 exhibited equal or greater potency than ciprofloxacin against C. freundii, P. mirabilis, P. rettgeri, P. stuartii, and Serratia marcescens. In general, the Enterobacteriaceae were more uniformly susceptible to GV129606 than piperacillin, ceftazidime, cefpirome and gentamicin. Table 3 shows the susceptibilities to GV129606 of selected isolates of C. freundii, E. cloacae, and S. marcescens which produce inducible group 1 ␤-lactamases (1), conferring resistance to expanded-spectrum cephalosporins. GV129606 showed a MIC 90 range of 0.5 to 2 g/ml, similar to the activity obtained against the same genera not expressing the resistance. Meropenem was also indifferent to the presence of the enzymes (MIC 90 s, 0.06 to 0.5 g/ml). With the exception of cefpirome which exhibited an MIC 90 of 4 g/ml against C. freundii, none of the isolates tested were susceptible to piperacillin, ceftazidime, or cefpirome.
Gram-negative nonfermentative bacterial species were also tested. The majority of strains of Acinetobacter calcoaceticus, including those resistant to ␤-lactams (with the exception of carbapenems) and to gentamicin, were sensitive to meropenem, ciprofloxacin, and GV129606. Against Neisseria gonorrhoeae, GV129606 was as active as cefpirome, but it was more active than ceftazidime, piperacillin, and gentamicin (MIC 90 s, 0.5, Ͼ32, and 16 g/ml, respectively). Ciprofloxacin and meropenem were the most active agents tested against this species.
All of the test compounds showed good activity against P. aeruginosa (ceftazidime-sensitive category), as the MIC 90 s ranged from 1 to 4 g/ml, with only cefpirome exhibiting less potency (MIC 90 , 8 g/ml). However, there was greater differentiation against the P. aeruginosa ceftazidime-resistant category where ciprofloxacin was the most active (MIC 90 , 0.25 g/ml), GV129606, meropenem, and gentamicin were moderately active (MIC 90 , 8 g/ml), and piperacillin, ceftazidime, and cefpirome were without activity.
Against isolates of imipenem-resistant P. aeruginosa and Stenotrophomonas maltophilia, none of the test compounds had useful activity (data not shown). The in vitro activities recorded for GV129606 against H. influenzae and Haemophilus parainfluenzae were unexpectably 8-to 32-fold less active than the other ␤-lactams tested and 128-fold less active than ciprofloxacin. Ciprofloxacin was the most active agent tested against this species: the MIC 90 s were Յ0.03 g/ml. Against Moraxella catarrhalis, GV129606 was as active as ciprofloxacin and ceftazidime (MIC 90 , 0.12 g/ml) and it was one-or twofold more active than piperacillin, cefpirome, and gentamicin. Meropenem was the most active agent against this species (MIC 90 , 0.03 g/ml).
The susceptibilities of the major anaerobic pathogenic species to GV129606 compared to the therapeutic agents clindamycin, piperacillin, cefoxitin, and metronidazole are reported in Tables 4 and 5. GV129606 was compared to other agents against individual anaerobic isolates representing the Clostridium, Peptostreptococcus, Streptococcus, Bacteroides, and Fusobacterium spp. Clostridium difficile was generally the least susceptible species, being inhibited by metronidazole at 0.2 and 0.5 g/ml, whereas GV129606, meropenem, and piperacillin were 16-to 40-fold less active. GV129606 inhibited all of the other anaerobic isolates tested, including a metronidazole-resistant Bacteroides fragilis, with a MIC range of Յ0.015 to 0.5 g/ml, similar to that of meropenem. Metronidazole was the most uniformly active agent tested, whereas piperacillin and cefoxitin gave a broad range of susceptibilities. A larger number of clinical isolates of C. perfringens and B. fragilis were tested. The in vitro activities of GV129606 against both species have been confirmed (Table  5 ) to be markedly superior to cefoxitin and piperacillin against The results of experiments determining the activities of GV129606 against strains possessing known ␤-lactamases are shown in Table 6 . GV129606 was highly active against transconjugant strains with TEM, OXA, SHV, and PSE ␤-lactamase series, the PC1 penicillinase, the broad-spectrum chromosomal enzyme K1, and the cephalosporinase P99. The activity of GV129606 was decreased against E. coli possessing a metallo-␤-lactamase (L1) similar to meropenem. MICs of GV129606 and meropenem against these organisms were lower than those of piperacillin and ceftazidime.
In vivo efficacy. The protective efficacy of GV129606 against experimental bacteremic infection caused by selected grampositive and -negative pathogens in mice was compared with those of meropenem, cefpirome, ciprofloxacin, and gentamicin. Table 7 shows that GV129606 was the most effective test compound against S. aureus and S. epidermidis. GV129606 was effective at Յ0.05 mg/kg of body weight/dose, the next best compound being gentamicin (Յ0.11 mg/kg/dose). Meropenem, cefpirome, and ciprofloxacin exhibited therapeutic ranges 7-to Ͼ100-fold less efficacious than GV129606 against these pathogens. Likewise, S. pneumoniae was exquisitely sensitive to GV129606 therapy (0.009 mg/kg/dose) and cefpirome (0.01 mg/kg/dose). GV129606 was at least 10-fold more efficacious than meropenem, ciprofloxacin, and gentamicin. Against the Enterobacteriaceae, meropenem and GV129606 were the most active test compounds in terms of the overall range of ED 50 s, all curative doses being between 0.03 to 0.18 and 0.03 to 0.71 mg/kg/dose, respectively (Table 8) . Although cefpirome and ciprofloxacin were the most active antibiotics against certain individual strains, they displayed wider ranges of therapeutic efficacy than GV129606 (0.01 to 11.76 and Ͻ0.006 to 1.67 mg/kg/dose, respectively). Gentamicin was therapeutically ineffective at the doses tested against E. cloacae and C. freundii. For infections caused by two strains of P. aeruginosa, (one of which is ceftazidime resistant), ciprofloxacin was the most effective antibiotic, inhibiting both strains at Յ0.15 mg/kg/dose, while gentamicin was several orders of magnitude less efficacious and cefpirome was poorly active. Against the same strains, GV129606 was as effective as meropenem, (exhibiting ED 50 s of Ͻ0.5 mg/kg/dose), with no significant differences in efficacy against resistant and susceptible P. aeruginosa strains.
DISCUSSION
GV129606 is a new injectable trinem belonging to the ␤-lactam class with broad-spectrum antibacterial activity against gram-positive and -negative aerobic and anaerobic bacteria. A feature of GV129606 was its in vitro activity against gram- positive cocci. Its in vitro potencies against methicillin-susceptible staphylococci and streptococci were superior to those of ciprofloxacin and gentamicin, especially against streptococci, and also showed a significantly better activity than the injectable ␤-lactams tested. Against S. pneumoniae, including penicillin-resistant strains, GV129606 was as active as meropenem and cefpirome. GV129606 possessed good activity against the members of the family Enterobacteriaceae, including ␤-lactamase-producing pathogens, which cause resistance problems to the expanded-spectrum cephalosporins in the clinic (5, 8, 10) . It also exhibited activity against carbapenem-susceptible P. aeruginosa similar to that of meropenem, including ceftazidime-resistant strains. Against these clinical isolates, it is significantly more active than injectable penicillins, cephalosporins, and gentamicin. Given the general good potency against gram-negative bacteria, notable exceptions were the Proteeae and Haemophilus spp. for which GV129606 was significantly less potent than meropenem. Ciprofloxacin showed the best spectrum of activity against gram-negative bacteria, with the exception of P. stuartii and a few strains of S. marcescens and Proteus spp.
GV129606 exhibited a greater potency and a wider spectrum, particularly against gram-negative pathogens, than the semisynthetic penicillin piperacillin. Against gram-negative bacteria, GV129606 showed an activity broadly comparable with those of the cephalosporins, but it had superior activity against a range of gram-positive organisms. Although cephalosporins such as cefpirome show little activity against enterococci or anaerobes, GV129606 was moderately active against enterococci and exhibited potent antianaerobe activity. Fluoroquinolones exhibit excellent activity against members of the family Enterobacteriaceae. Although GV129606 was not as active as ciprofloxacin against enteric bacteria, it possessed more than sufficient activity for clinical utility. However, GV129606 exhibited activity superior to that of ciprofloxacin against gram-positive bacteria and anaerobes.
GV129606 is a new parenteral trinem antibiotic, stable against the most common clinically relevant ␤-lactamases and possessing a very broad antibacterial spectrum, superior to any cephalosporin or penicillin, comparable to that of meropenem. Against pathogenic anaerobic bacteria, its activity is similar to that of metronidazole. This potency is also reflected in its efficacy in generalized infections in mice. GV129606 is the most effective antistaphylococcal agent and has activity comparable to that of meropenem against the gram-negative organisms, despite slightly inferior MICs in vitro.
In conclusion, GV129606 appears to be a promising injectable trinem antibiotic for the treatment of infections caused by a variety of gram-positive, gram-negative, and anaerobic bacteria encountered in general practice and in the treatment of moderate to severe infections in hospital outpatients.
